| 000 | 01694 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517153417.0 | ||
| 264 | 0 | _c20180518 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1533-4023 | ||
| 024 | 7 |
_a10.1097/FJC.0000000000000503 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJain, Moon | |
| 245 | 0 | 0 |
_aAntihypertensive Drugs Aliskiren, Nebivolol, and Olmesartan Reduce Hypertension by Reducing Endothelial Microparticles and Regulating Angiogenesis. _h[electronic resource] |
| 260 |
_bJournal of cardiovascular pharmacology _cSep 2017 |
||
| 300 |
_a176-183 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAmides _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCell-Derived Microparticles _xdrug effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aFumarates _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNebivolol _xadministration & dosage |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aTetrazoles _xadministration & dosage |
| 700 | 1 | _aBhosale, Vivek | |
| 700 | 1 | _aTripathi, Dipti | |
| 700 | 1 | _aSingh, Himalaya | |
| 700 | 1 | _aPal, Niharika | |
| 700 | 1 | _aHanif, Kashif | |
| 700 | 1 | _aJagavelu, Kumaravelu | |
| 773 | 0 |
_tJournal of cardiovascular pharmacology _gvol. 70 _gno. 3 _gp. 176-183 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/FJC.0000000000000503 _zAvailable from publisher's website |
| 999 |
_c27167474 _d27167474 |
||